NCT04353973Completed
Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients
A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients
Source: ClinicalTrials.gov · Last updated 29 Jul 2025
Brief summary (registry, in English)
This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved cognitive and affective outcomes when compared to the standard of care delivery model.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 256 (actual)
- First submitted
- 3 Apr 2020
- Start date
- 17 Aug 2020
- Primary completion date
- 15 Aug 2024
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Prostate cancer, Pancreatic cancer, Ovarian cancer
- NCT number
- NCT04353973
What you commit to
- Study type: Interventional
- Participants enrolled: 256
- From 17 Aug 2020 to the primary completion date, 15 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Communication difficulties such as:
- Uncorrected or uncompensated hearing and/or vision impairment
- Uncorrected or uncompensated speech defects
- Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks
Who the study is looking for
- 18 years of age or older
- Speak and understand English
- Male or Female
- A personal history of one or more of the following:
- metastatic breast cancer
- advanced ovarian cancer (Stage III-IV)
- metastatic pancreatic cancer
- metastatic prostate cancer
- Naive to previous cancer germline genetic testing
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abramson Cancer Center at University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.